Corrigendum: Clinical efficacy, safety and tolerability of a new subcutaneous immunoglobulin 16.5% (Octanorm [Cutaquig®]) in the treatment of patients with primary immunodeficiencies.
Front Immunol
; 13: 1110388, 2022.
Article
em En
| MEDLINE
| ID: mdl-36605207
ABSTRACT
[This corrects the article DOI 10.3389/fimmu.2019.00040.].
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article